Induced Pluripotent Stem Cells Production Industry Overview
The induced pluripotent stem cells production market was valued at USD 948.29 million in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 8.0% from 2021 to 2028.
Induced pluripotent stem cells have several advantages over Embryonic Stem Cells (ESCs), such as avoiding the stem cell-associated ethical implications and maximum flexibility in cell-based research applications. These advantages have offered induced pluripotent stem cells (iPSCs) significant momentum in recent years, creating a favorable market for entities operating in the market. The robust pipeline for iPSC-derived cell therapeutics coupled with emerging applications of iPSCs is anticipated to accelerate the market growth. As of 2021, the total number of iPSC clinical trials has risen to 54. For instance, Allele Biotechnology Pharmaceuticals is developing a diabetics drug from iPSC-derived pancreatic beta cells.
Gather more insights about the market drivers, restrains and growth of the Global Induced Pluripotent Stem Cells Production Market
Moreover, a substantial number of companies and organizations are exploring the potential of iPSCs in cell therapeutics targeted at the treatment of different diseases, which, in turn, will stimulate market growth. Moreover, the rising popularity of regenerative medicines is further contributing to market growth. iPSCs are commonly used for the regeneration of tissue-specific cells for transplantation to patients of different injuries. In addition, researchers are showing interest in using iPSCs for ex-vivo expansion of various blood components. iPSCs are used for the production of red blood cells, which could be used for the generation of blood.
The COVID-19 pandemic has increased the iPSC-based research and development activities. In addition, researchers are keen to find new therapies and treatments to combat this pandemic. In this scenario, iPSCs are powerful research tools to produce normal different cell types relevant for SARS-CoV-2. Moreover, iPSCs are important to generate physiologically relevant human-cell models that can replicate the pathophysiology of COVID-19, thus aiding drug testing.
For instance, a research team at Newcastle University, U.K., has successfully developed a lung cell model from iPSCs that can be used to understand how SARS-CoV-2 infects the airways. High costs associated with iPSC production as well as tumorigenicity, immunogenicity, and heterogeneity may hamper the market growth. The iPS cells may exhibit chromosomal instability, loss of heterozygosity, copy number variant, and genetic instability over a while in in-vitro culture. Moreover, iPSCs are mainly produced and expanded with a feeder layer system, which can generate a high lot-to-lot variability, safety regulatory concerns and affect the scalability of the process.
Browse through Grand View Research's Biotechnology Industry Research Reports
- Recombinant Proteins Market: The global recombinant proteins market size was valued at USD 1.75 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 12.00% from 2022 to 2030.
- Cell-free Protein Expression Market: The global cell-free protein expression market size was valued at USD 229.7 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 8.48 % from 2022 to 2030.
Induced Pluripotent Stem Cells Production Market Segmentation
Grand View Research has segmented the global induced pluripotent stem cells production market on the basis of process, product, workflow, application, end-use, and region:
iPSCs Production Process Outlook (Revenue, USD Million, 2017 - 2028)
- Manual
- Automated
iPSCs Production Workflow Outlook (Revenue, USD Million, 2017 - 2028)
- Reprogramming
- Cell Culture
- Cell Characterization/Analysis
- Engineering
- Others
iPSCs Production Product Outlook (Revenue, USD Million, 2017 - 2028)
- Instruments/Devices
- Automated Platforms
- Consumables Kits
- Services
iPSCs Production Application Outlook (Revenue, USD Million, 2017 - 2028)
- Drug Development and Discovery
- Regenerative Medicine
- Toxicology Studies
- Others
iPSCs Production End-use Outlook (Revenue, USD Million, 2017 - 2028)
- Research Academic Institutes
- Biotechnology Pharmaceutical Companies
- Hospitals Clinics
iPSCs Production Regional Outlook (Revenue, USD Million, 2017 - 2028)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East Africa
Market Share Insights
- January 2021: Evotec SE received USD 6 million from Bristol Myers Co. for their iPS cell-based neuroscience partnership.
- December 2020: REPROCELL launched a personalized iPSC generation service alongside a new B2C website to support the “Personal iPS” service. This service prepares and stores an individual’s iPSCs for the regenerative treatment of future injury or illness.
- October 2020: Axol Biosciences introduced Multi-Electrode Array (MEA) screening for human iPSC-derived cells to expand its service offering.
- January 2019: New York Stem Cell Foundation Research Institute and Ngene Therapeutics Inc. entered into a partnership to develop the treatment of new diseases that leverage human stem cell research and novel gene-editing techniques.
Key Companies profiled:
Some of the key participants operating in the global induced pluripotent stem cells production market include:
- Lonza
- Axol Biosciences Ltd.
- Evotec
- Hitachi Ltd.
- Merck KGaA
- REPROCELL, Inc.
- Fate Therapeutics
- Thermo Fisher Scientific, Inc.
- StemCellFactory III
- Applied StemCell, Inc.
Order a free sample PDF of the Induced Pluripotent Stem Cells Production Market Intelligence Study, published by Grand View Research.
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
